Document:

EX-10.1

 Exhibit 10.1 

SEPARATION AGREEMENT AND RELEASE 

This Separation Agreement and Release (this “Agreement”) is made between Checkmate Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), and Barry Labinger (the “Executive”). The Company together with the Executive shall be referred to as the “Parties”. 

WHEREAS, the Parties entered into an Employment Agreement dated November 26, 2018 (as amended by Amendment No. 1 to
Employment Agreement, the “Employment Agreement”); 
 WHEREAS, pursuant to the Employment Agreement, the Company and
the Executive each retained the right to terminate the Executive’s employment by the Company without any breach of the Employment Agreement under the circumstances set forth in Section 2 of the Employment Agreement; 

WHEREAS, the Executive’s employment will end on October 27, 2021 (the “Date of Termination”) pursuant to
Section 2(b)(ii)(C) of the Employment Agreement; 
 WHEREAS, this Agreement is the “Separation Agreement and
Release” referred to in the Employment Agreement; 
 WHEREAS, if the Executive enters into, does not revoke and complies
with this Agreement, the Executive will be eligible to receive the severance pay and benefits as described in this Agreement pursuant to Section 4(c) of the Employment Agreement (as amended); and 

WHEREAS, the Parties agree that this Agreement satisfies the notice requirement set forth in Section 2(b)(ii)(C) of the Employment
Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the
Parties hereby agree as follows: 
 1. Ending of Employment. The Executive’s employment with the Company will end on the Date of
Termination. During the period between October 22, 2021 and the Date of Termination the Executive shall not perform services or communicate on behalf of the Company without prior authorization from the Company’s Board of Directors (the
“Board”). Consistent with the terms of the Employment Agreement, the Executive shall be deemed to have resigned from all officer and director positions that the Executive holds with the Company or any of its respective subsidiaries and
affiliates upon the Date of Termination, including as a member of the Board. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. By entering into this Agreement, the
Executive acknowledges and agrees that the payments and benefits set forth in this Agreement are the exclusive payments and benefits to be paid to the Executive in connection with the ending of his employment and that he is not entitled to any other
severance pay, benefits or equity rights, or garden leave pay including without limitation pursuant to any severance plan, program or arrangement. 

 2. Accrued Obligations. The Executive acknowledges and agrees that in connection with the
ending of his employment, and regardless of whether this Agreement becomes effective, the Company shall pay or provide to the Executive the following “Accrued Obligations” as set forth in Section 4(a) of the Employment Agreement:
(i) the portion of Executive’s Base Salary (as defined in the Employment Agreement) that has accrued prior to the Date of Termination and has not yet been paid; (ii) pay for earned but unused vacation time, and
(iii) the amount of any expenses properly incurred by Executive on behalf of Company prior to the Date of Termination and not yet reimbursed. Executive’s entitlement to any other compensation or benefit under any plan of Company
shall be governed by and determined in accordance with the terms of such plans, except as otherwise specified in this Agreement. 
 In addition, regardless
of whether this Agreement becomes effective, the Executive will be provided with information regarding the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) under separate cover. Any COBRA continuation
coverage will be at the Executive’s own cost, except as provided in Section 3(b) below. 
 3. Severance Pay and Benefits. In
exchange for the Executive entering into, not revoking and complying with this Agreement, the Executive will be entitled to the following “Severance Pay and Benefits”: 

(a) an amount equal to 12 months of the Executive’s Base Salary (the “Severance Amount”); and 

(b) if the Executive was participating in the Company’s group health, dental and/or vision plans immediately prior to the Date of Termination and
properly elects to continue health coverage under COBRA, then, the Company shall continue to provide Executive medical insurance coverage at no cost to Executive to the same extent that such insurance continues to be provided to similarly situated
executives at the time of Executive’s termination until the earliest of the following: (i) the first anniversary of the Date of Termination; (ii) the Executive’s eligibility for group medical plan benefits under any other
employer’s group medical plan or otherwise through other employment; or (iii) the cessation of the Executive’s continuation coverage rights under COBRA. Notwithstanding the foregoing, if the Company determines at any time that
its payments pursuant to this paragraph may be taxable income to the Executive or that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including,
without limitation, Section 2716 of the Public Health Service Act), then the Company may convert such payments to payroll payments directly to the Executive for the time period specified above; and such payments shall be subject to
tax-related deductions and withholdings and shall be paid on the Company’s regular payroll dates. Any other premiums or costs of COBRA continuation coverage not provided above (including, without limitation, for any COBRA coverage after the
time period set forth above) shall be at the sole expense of the Executive. 
 The amounts payable under this Section 3, to the extent taxable, shall
be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; Each payment pursuant to this Agreement is intended to constitute a
separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). 

 4. Equity. The Executive’s equity incentive award(s) will remain subject in all respects
to the Company’s 2015 Stock Option and Grant Plan and 2020 Stock Option and Grant Plan and the applicable stock option agreement(s) (together, the “Equity Documents”), provided if the Executive enters into this Agreement: (i)
all of the Executive’s unvested time-based equity awards that would have vested on or before January 27, 2022 shall accelerate and become vested as of the Date of Termination; and (ii) the Company shall extend the exercise period with respect
to the Executive’s vested stock options from ninety (90) days from the Date of Termination to July 27, 2022 (the “Extended Exercise Period”), provided that any stock option subject to this Extended Exercise Period shall cease
to be treated for tax purposes as an incentive stock option. 
 5. General Release. In consideration for, among other terms, the Severance Pay
and Benefits, to which the Executive acknowledges that he would otherwise not be entitled, the Executive irrevocably and unconditionally releases and forever discharges the Company, all of its affiliated and related entities, its and their
respective predecessors, successors and assigns, its and their respective employee benefit plans and the fiduciaries of such plans, and the current and former officers, directors, stockholders, employees, attorneys, accountants, and agents of each
of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”)
that, as of the date when the Executive signs this Agreement, he has, ever had, now claims to have or ever claimed to have had against any or all of the Releasees. This release includes, without limitation, the complete waiver and release of all
Claims: relating to the Executive’s employment by and termination of employment with the Company; arising out of or relating to the Employment Agreement or any other agreement between the Executive and any of the Releasees, provided, however,
the Executive does not release any Claim arising out of or relating to the Checkmate Pharmaceuticals, Inc. Officer Indemnification Agreement (the “Indemnification Agreement”), the right to receive Severance Pay and Benefits pursuant
to this Agreement, and the treatment of the Executive’s equity awards as provided in the Equity Documents as amended by this Agreement; of breach of express or implied contract; of wrongful termination of employment whether in contract or tort;
of violation of public policy; of intentional, reckless, or negligent infliction of emotional distress; of breach of any express or implied covenant of employment, including the covenant of good faith and fair dealing; of interference with
contractual or advantageous relations, whether prospective or existing; of deceit or misrepresentation; of discrimination or retaliation under state, federal or municipal law, including, without limitation, Title VII of the Civil Rights
Act of 1964, the Americans with Disabilities Act, the Age Discrimination in Employment Act, and the Massachusetts Fair Employment Practices Act; of whistleblower retaliation; of fraud; under any other federal, state or local statute,
rule, ordinance or regulation; of promissory estoppel or detrimental reliance; for wages, bonuses, incentive compensation, stock, stock options, vacation pay, severance allowances or entitlements, and any other compensation or benefits, either under
the Massachusetts Wage Act, or otherwise; of slander, libel, defamation, disparagement, intentional infliction of emotional distress, personal injury, negligence or other torts; for damages or other remedies of any sort, including, without
limitation, compensatory damages, punitive damages, injunctive relief, attorneys’ fees, experts’ fees, medical fees or expenses, costs and disbursements. The Executive understands that this general release of Claims includes, without
limitation, any and all Claims related to the Executive’s employment by the Company (including without limitation, any Claims against the Company in respect of any stock-based awards of any kind) and the termination of his employment, and all
Claims in his capacity as a Company 

 
stockholder arising up to and through the date that the Executive enters into this Agreement. The Executive understands that this general release does not extend to any rights or Claims that may
arise out of acts or events that occur after the date on which the Executive signs this Agreement, to Claims that cannot be released as a matter of law or to any rights to any indemnification and defense that the Executive has with the Company. This
release does not affect the Executive’s rights or obligations under this Agreement, nor shall it affect the Executive’s rights, if any, to unemployment compensation benefits or to workers’ compensation. The Executive agrees not to
accept damages of any nature, other equitable or legal remedies for the Executive’s own benefit or attorney’s fees or costs from any of the Releasees with respect to any Claim released by this Agreement. The Executive represents that he
has not assigned to any third party and has not filed with any agency or court any Claim released by this Agreement. 
 6. Return of Property.
The Executive acknowledges and agrees that he is required to return all Company property to the Company pursuant to Section 6 of the Employment Agreement and the Restrictive Covenants Agreement (as defined below) upon the ending of his
employment. By entering into this Agreement, the Executive confirms that he has returned to the Company all Company property, including, without limitation, any Company laptop, computer equipment, software, keys and access cards, credit cards, files
and any documents (including computerized data and any copies made of any computerized data or software) containing information concerning the Company, its business or its business relationships. After returning all Company property, the Executive
agrees to delete and finally purge any duplicates of files or documents that may contain Company or customer information from any non-Company computer or other device that remains the Executive’s property after the Date of Termination. 

7. Communications. The Executive agrees that he will not communicate about his departure with anyone until after the Board has made a formal
written announcement about the Executive’s departure (together, the “Company Announcement”); provided that the Executive may communicate with his tax advisors, attorneys and spouse about his departure before the Company
Announcement, provided further that the Executive first advises such persons not to reveal information about the Executive’s departure and each such person agrees. Once the Company has made the Company Announcement, the Executive agrees to
limit any communications regarding his departure to statements consistent with the Company Announcement. 
 8. Restrictive Covenants
Agreement. The Executive acknowledges and reaffirms his obligations under the Employee Confidentiality, Assignment, and Noncompetition Agreement dated as of December 5, 2018 (the “Restrictive Covenants Agreement”). The
Restrictive Covenants Agreement remains in full force and effect and is incorporated by reference herein as a material term of this Agreement. For the avoidance of doubt, this Agreement is being entered into in connection with the cessation of
Executive’s employment and the Executive agrees that the noncompetition restrictions in the Restrictive Covenants Agreement shall apply during the Restricted Period, notwithstanding the fact that the Executive’s employment was terminated
without Cause for the purposes of the Employment Agreement. In connection therewith, the Company agrees that the scope of the “business” set forth in Section 8(c) of the Restrictive Covenants Agreement in which the
Company engages or is actively planning to engage shall mean a business that develops, manufactures or markets any products arising out of toll-like receptor 9 (TLR9) agonists. Accordingly, the Severance Pay and Benefits represent the full pay to
which the Executive is entitled and the Executive is not entitled to any “garden leave pay” or other consideration pursuant to Section 8(c) of the Restrictive Covenants Agreement. 

 9. Cooperation. The Executive shall reasonably cooperate fully with the Company, including in
(i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the
Company, and (ii) the investigation, whether internal or external, of any matters about which the Company reasonably believes the Executive may have knowledge or information. The Executive’s full cooperation in connection with such
claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times,
taking into account, among other things, the Executive’s employment obligations. The Executive also shall reasonably cooperate with the Company in connection with any investigation or review of any federal, state or local regulatory authority
as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the
Executive’s performance of obligations pursuant to this Section 9, provided that the Company shall provide mutually agreed upon hourly compensation in respect of services that relate to non-litigation matters. 

10. Continuing Obligations; Termination of Payments; Injunctive Relief. The Executive acknowledges that his right to the Severance Pay and
Benefits are conditioned on his full compliance with Sections 6 through 9 of this Agreement, the Restrictive Covenants Agreement and Sections 5 and 6 of the Employment Agreement. The Restrictive Covenants Agreement and Sections 5 and 6 of the
Employment Agreement are incorporated by reference as material terms of this Agreement, and, together with Sections 6 through 9 of this Agreement, shall be referred to as the “Continuing Obligations”. In the event that the Executive fails
to comply with any of the Continuing Obligations, in addition to any other legal or equitable remedies it may have for such breach, the Company shall have the right to terminate payments provided under this Agreement other than the Accrued
Obligations. Such termination in the event of a breach by the Executive of the Continuing Obligations shall not affect the general release in Section 5 of this Agreement or the Executive’s obligation to comply with the Continuing
Obligations and shall be in addition to, and not in lieu of, the Company’s rights to other legal and equitable remedies that the Company may have. Further, the Executive agrees that it would be difficult to measure any harm caused to the
Company that might result from any breach by the Executive of any of the Continuing Obligations and that, in any event, money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if he breaches, or
proposes to breach, any portion of the Continuing Obligations, then the Company shall be entitled, in addition to all other remedies it may have, to an injunction or other appropriate equitable relief to restrain any such breach, without showing or
proving any actual damage to the Company and without the necessity of posting a bond, and to seek to recover the Company’s attorneys’ fees and costs associated with any such breach by the Executive. 

 11. Absence of Reliance. This Agreement is a legally binding document and the Executive’s
signature will commit the Executive to its terms. In signing this Agreement, the Executive agrees that he is not relying upon any promise or representations made by anyone at or on behalf of the Company. 

12. Protected Disclosures. Nothing in this Agreement or otherwise limits the Executive’s: (i) obligation to testify truthfully in any
legal proceeding; (ii) right to file a charge, claim or complaint with any federal agency (such as the Equal Employment Opportunity Commission) or any state or local governmental agency or commission (together, a “Government
Agency”), provided that the Executive waives any right to monetary or other individualized relief (either individually or as part of any collective or class action); provided further that nothing in this Agreement limits any right that the
Executive may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission; or (iii) ability to communicate with any Government Agency or otherwise participate in any investigation or
proceeding that may be conducted by any Government Agency. 
 13. Time for Consideration; Effective Date. The Company advises the Executive to
consult with an attorney before entering into this Agreement. The Executive acknowledges that he has carefully read and fully understands all of the provisions of this Agreement and that the Executive is voluntarily and knowingly entering into this
Agreement. The Executive acknowledges that he has been given the opportunity to consider this Agreement for 21 days before executing it (the “Consideration Period”). To accept this Agreement, the Executive must return a signed,
unmodified original or PDF copy of this Agreement so that it is received by the undersigned at or before the expiration of the Consideration Period. If the Executive signs this Agreement before the end of the Consideration Period, the Executive
acknowledges that such decision was entirely voluntary and that the Executive had the opportunity to consider this Agreement for the entire Consideration Period. For the period of seven business (7) days from the date when the Executive signs
this Agreement, the Executive has the right to revoke this Agreement by written notice to the undersigned, provided that such notice is delivered so that it is received at or before the expiration of the seven business day revocation period. This
Agreement shall not become effective or enforceable during the revocation period. This Agreement shall become effective on the first business day following the expiration of the revocation period (the “Effective Date”). 

14. Enforceability. The Executive acknowledges that, if any portion or provision of this Agreement or the Continuing Obligations shall to any
extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision shall be
valid and enforceable to the fullest extent permitted by law. 
 15. Entire Agreement. This Agreement, including the Continuing Obligations,
constitute the entire agreement between the Executive and the Company concerning the Executive’s relationship with the Company, and supersede and replace any and all prior agreements and understandings between the Parties concerning the
Executive’s relationship with the Company including, without limitation, the Employment Agreement (except for those sections preserved in the Continuing Obligations), provided that the Equity Documents and the Indemnification Agreement shall
continue to be in full force and effect in accordance with their terms. 

 16. Waiver; Amendment. No waiver of any provision of this Agreement, including the Continuing
Obligations, shall be effective unless made in writing and signed by the waiving party. The failure of either Party to require the performance of any term or obligation of this Agreement or the Continuing Obligations, or the waiver by either Party
of any breach of this Agreement or the Continuing Obligations shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may not be modified or amended except in a writing
signed by both the Executive and a duly authorized officer of the Company. 
 17. Taxes. The Company shall undertake to make deductions,
withholdings and tax reports with respect to payments and benefits under this Agreement and in connection with other compensation matters to the extent that it reasonably and in good faith determines that it is required to make such deductions,
withholdings and tax reports. Payments under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any
adverse tax effect associated with any payments or benefits made to the Executive in connection with the Executive’s employment with the Company. 

18. Section 409A. The Parties intend that this Agreement will be administered in accordance with Section 409A of the Internal Revenue
Code of 1986, as amended (the “Code”). To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder
comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The Company makes no representation or warranty
and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the
conditions of, such Section. 
 19. Acknowledgment of Wage and Other Payments. The Executive acknowledges and represents that, except as
expressly provided in this Agreement, the Executive has been paid all wages, bonuses, compensation, benefits and other amounts that any of the Releasees has ever owed to the Executive. The Executive is not entitled to any bonus, incentive
compensation or other compensation except as specifically set forth in this Agreement. 
 20. Governing Law; Interpretation. This Agreement
shall be interpreted and enforced under the laws of the Commonwealth of Massachusetts without regard to conflict of law principles. In the event of any dispute, this Agreement is intended by the Parties to be construed as a whole, to be interpreted
in accordance with its fair meaning, and not to be construed strictly for or against either Party or the “drafter” of all or any portion of this Agreement. 

21. Consent to Jurisdiction. The parties hereby consent to the exclusive jurisdiction of the state and federal courts of the Commonwealth of
Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement
(whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. 

 22. Assignment; Successors and Assigns. Neither the Executive nor the Company may make any
assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the
Restrictive Covenants Agreement) without the Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers
all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s respective successors, executors,
administrators, heirs and permitted assigns. In the event of the Executive’s death after the Date of Termination but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue
such payments to the Executive’s beneficiary designated in writing to the Company prior to the Executive’s death (or to the Executive’s estate, if the Executive fails to make such designation). 

23. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an
original, but all of which together shall constitute one and the same document. Electronic and pdf signatures shall be deemed to be of equal force and effect as originals. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have executed this
Agreement on the date(s) indicated below. 
  

			
	COMPANY:
	
	CHECKMATE PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Michael Powell

	Name:	 	Michael Powell
	Title:	 	Chairman of the Board of Directors
		
	Date:	 	October 27, 2021
	
	EXECUTIVE:
	
	 /s/ Barry Labinger

	Name:	 	Barry Labinger
		
	Date:	 	October 27, 2021EX-10.2

 Exhibit 10.2 

October 22, 2021 
 Via Email 

Alan Fuhrman 
 Dear Alan: 

Checkmate Pharmaceuticals, Inc. (the “Company”) is pleased to extend you an offer of employment as the Interim Chief Executive Officer
(“Interim CEO”), reporting to the Board of Directors of the Company (the “Board”), effective October 27, 2021 (the “Effective Date”) and continuing until the date that a new Chief Executive
Officer (the “New CEO”) commences employment with the Company, unless your employment is sooner terminated by you or the Board (the “Term”). The terms and conditions of your employment, should you accept this offer,
are set forth in the below agreement (the “Agreement”). 
 1. Position. As the Interim CEO, you shall have such powers and
duties as may from time to time be prescribed by the Board, which shall include, without limitation, working to identify possible CEO candidates and, at the Board’s request, facilitating the hire of the New CEO. In addition, you shall continue
to serve as member of the Board during the Term, provided that you shall immediately resign from the Audit Committee of the Board. At all times during the Term, you shall devote your full working time and efforts to the business and affairs
of the Company. Notwithstanding the foregoing, you may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities do not materially
interfere with the performance of your duties to the Company as provided in this Agreement. 
 2. Salary. During the Term, you will no longer
receive cash compensation in the form of director’s fees. Instead, the Company will pay you a base salary at the rate of $525,000 per year, payable in accordance with the Company’s standard payroll schedule and subject to applicable
deductions and withholdings (the “Base Salary”). The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices. 

3. Expenses. You will be entitled to receive prompt reimbursement for all reasonable expenses that you incur during the Term in performing
services hereunder, in accordance with the policies and procedures then in effect and established by the Company. 
 4. Temporary Housing. The
Company will reimburse you up to $6,500 per month for temporary housing in Cambridge, MA. 
 5. Employee Benefits. During the Term, you will
be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans. 

  
 1 

 6. Equity. 

(a) Interim CEO Stock Option Award. In connection with the commencement of your employment as Interim CEO, subject to the approval of
the Compensation Committee of the Board, you shall be granted a stock option to purchase 246,671 shares of the Company’s common stock (the “Interim CEO Stock Option Award”) at an exercise price per share equal to the closing
price of the Company’s common stock on the Nasdaq Global Market on the date of grant (or if no closing market price is reported for such date, the closing market price on the immediately preceding date for which a closing market price is
reported). The Stock Option Award will vest in equal monthly installments over the twelve months following the Effective Date, subject to your continued Service Relationship (as defined in the Checkmate Pharmaceuticals, Inc. 2020 Stock Option and
Incentive Plan (as amended and/or restated from time to time) (the “Plan”)) with the Company through each applicable vesting date. The Stock Option Award will be subject to all terms and conditions and other provisions set forth in
Plan and the applicable Stock Option Award (such agreement, with the, the “Equity Documents”), which you will be required to sign as a condition to be receiving the Stock Option Award. If the Company hires a New CEO before the
Interim CEO Stock Option Award is fully vested, the Board has the option (and will consider) accelerating the vesting of then outstanding Interim CEO Stock Option Award. 

(b) Existing Equity Awards. During the Term, you will continue to vest in your existing equity awards, subject to the terms of the
applicable equity award agreements and equity incentive plan(s) (collectively, the “Existing Equity Award Documents”). There will be no break in services from your status as an independent director and the commencement of employment
as Interim CEO pursuant to this Agreement. 
 7. At-will Employment. At all times your employment is
“at will,” meaning you or the Company may terminate it at any time. Your last day of employment is referred to herein as the “Date of Termination.” In the event of the ending of your employment for any reason, the Company
shall pay you (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 3 of this Agreement) on or before the time required by law but in no event more than 30
days after the Date of Termination; and (ii) any vested benefits you may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of
such employee benefit plans (the “Accrued Obligations”). Other than the Accrued Obligations, you will not be entitled to any compensation from the Company in connection with the ending of your employment. 

8. Confidential Information and Restricted Activities. You will be required to sign, as a condition of your employment, the
Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement that is enclosed with this Agreement (the “Restrictive Covenant
Agreement”). This offer is conditioned on your representation that you are not subject to any confidentiality, noncompetition, nonsolicitation, invention assignment or other agreement that restricts your employment activities or that may
affect your ability to devote full time and attention to your work at the Company. You further represent that you have not used and will not use or disclose any trade secret or other proprietary right of any previous employer or any other party.

 9. Withholding. All payments made by the Company to you under this Agreement shall be net of any tax or other amounts
required to be withheld by the Company under applicable law. 

  
 2 

 10. Entire Agreement. This Agreement, together with the Restrictive Covenant
Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether
written, oral or implied) between you and the Company related to the subject matter herein, provided, however, and notwithstanding the foregoing, the Existing Equity Award Documents, and the indemnification agreement signed by you shall
remain in effect in accordance with their terms, and Sections 9 through 20 of the Consulting Agreement shall remain in effect in accordance with their terms. 

11. Assignment. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law
or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the
Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and
each of your and its respective successors, executors, administrators, heirs and permitted assigns. 
 12. Other Terms. As
with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
taken to be an original; but such counterparts shall together constitute one and the same document. 
 [Signature page follows.] 

  
 3 

 We are excited about your willingness to serve as the Interim CEO and look forward to
continuing to work with you. You may indicate your agreement with these terms by signing and dating this Agreement, together with the signed Restrictive Covenant Agreement, and returning them both to me. If you have any questions, please do not
hesitate to contact me. 
  

	
	Very truly yours,
	
	 /s/ Michael Powell

	By: Michael Powell
	Its: Chairman of the Board

 Enclosure: Restrictive Covenant Agreement 

I have read and accept this Agreement: 
  

	
	 /s/ Alan Fuhrman

	Alan Fuhrman

 Dated: October 27, 2021 

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]